Today, TactoTek announced the opening of its new manufacturing and corporate headquarters facilities in Oulu, Finland, initiating a new phase of company growth.
“In early 2016, TactoTek’s project pipeline began growing dramatically and foreshadowed additional production capacity requirements and staffing needs, so we started evaluating alternatives for larger facilities,” noted Jussi Harvela, CEO.
“The new location is purpose-built for manufacturing injection molded structural electronics (IMSE),” emphasized Marko Suo-Anttila, SVP Engineering. “It uniquely contains all production steps of the IMSE manufacturing process, including printing decoration and electronics, surface mounting electronic components, high pressure thermoforming, and injection molding. And, our ISO 7 classification clean room facilities support demanding quality and consistency requirements.”
With its multi-disciplinary engineering teams, TactoTek collaborates with customers to adapt their traditional electronics designs into IMSE solutions. The company produces proofs-of-concepts and prototypes to refine product design and electronic functionality, and define the materials stack and processing parameters. TactoTek’s vertical integration enables rapid iterations to quickly optimize customer designs for mass production. Mass production is performed by TactoTek or a licensed manufacturer.
The European Regional Development Fund and the European Union’s Horizon 2020 Research and Innovation Programme have subsidized TactoTek production equipment and infrastructure.
Tower Semiconductor announced that it has signed silicon photonics agreements valued at $1.3 billion for…
The report is based on a survey of 150 CISOs and senior cybersecurity leaders from…
More than 200,000 voters will cast ballots using a secure and cryptographically verified online voting…
The multi-center study, involving 2,000 patients, will validate the CORA system - a breakthrough AI…
Molex, a global electronics leader and connectivity innovator, has completed the acquisition of Teramount Ltd.,…
This agreement marks the third expansion of its collaboration with AstraZeneca, building on collaborations in…